Professional
Added to YB: 2025-03-31
Pitch date: 2025-03-26
ERAS [bullish]
Erasca, Inc.
+143.24%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
Market Cap
$732.0M
Pitch Price
$1.48
Price Target
5.00 (+39%)
Dividend
N/A
EV/EBITDA
-3.40
P/E
-5.73
EV/Sales
N/A
Sector
Biotechnology
Category
value
Show full summary:
Erasca, Inc.: Raymond James Sees $5 Target Potential
ERAS initiated Outperform at Raymond James, $5 PT. Near-term naporafenib opportunity underappreciated. Thesis based on valuation gap vs RVMD's RMC-6236 and ERAS's ERAS-0015. RVMD at ~$5B EV, ERAS at cash. $5 PT implies ~$1B EV. Pan-RAS inhibitor market has room for 2nd mover.
Read full article (1 min)